Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021)

Immuneering's Preferred Stock Liabilities history spans 2 years, with the latest figure at $61.8 million for Q2 2021.

  • On a quarterly basis, Preferred Stock Liabilities rose 192.49% to $61.8 million in Q2 2021 year-over-year; TTM through Jun 2021 was $61.8 million, a 192.49% increase, with the full-year FY2020 number at $21.1 million, changed N/A from a year prior.
  • Preferred Stock Liabilities came in at $61.8 million for Q2 2021, up from $58.1 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $61.8 million in Q2 2021, with the low at $21.1 million in Q2 2020.